BRPI0921113A2 - tratamento de proteinopatias usando um inibidor de farnesil transferase. - Google Patents
tratamento de proteinopatias usando um inibidor de farnesil transferase.Info
- Publication number
- BRPI0921113A2 BRPI0921113A2 BRPI0921113A BRPI0921113A BRPI0921113A2 BR PI0921113 A2 BRPI0921113 A2 BR PI0921113A2 BR PI0921113 A BRPI0921113 A BR PI0921113A BR PI0921113 A BRPI0921113 A BR PI0921113A BR PI0921113 A2 BRPI0921113 A2 BR PI0921113A2
- Authority
- BR
- Brazil
- Prior art keywords
- proteinopathies
- treatment
- transferase inhibitor
- farnesyl transferase
- farnesyl
- Prior art date
Links
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 title 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11421908P | 2008-11-13 | 2008-11-13 | |
US12137308P | 2008-12-10 | 2008-12-10 | |
PCT/US2009/064375 WO2010056985A2 (en) | 2008-11-13 | 2009-11-13 | Treatment of proteinopathies using a farnesyl transferase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0921113A2 true BRPI0921113A2 (pt) | 2016-02-16 |
Family
ID=42170730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0921113A BRPI0921113A2 (pt) | 2008-11-13 | 2009-11-13 | tratamento de proteinopatias usando um inibidor de farnesil transferase. |
Country Status (9)
Country | Link |
---|---|
US (2) | US20110294794A1 (pt) |
EP (1) | EP2358370A2 (pt) |
JP (1) | JP2012508765A (pt) |
AU (1) | AU2009313906A1 (pt) |
BR (1) | BRPI0921113A2 (pt) |
CA (1) | CA2743709A1 (pt) |
IL (1) | IL212835A0 (pt) |
MX (1) | MX2011005095A (pt) |
WO (2) | WO2010057028A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100184803A1 (en) * | 2007-03-09 | 2010-07-22 | Link Medicine Corporation | Treatment of Lysosomal Storage Diseases |
CA2853945C (en) | 2011-10-31 | 2020-09-22 | The Johns Hopkins University | Methods and compositions for treatment of autism |
CA2881656C (en) | 2012-08-29 | 2023-07-11 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
KR20170086492A (ko) | 2014-10-30 | 2017-07-26 | 캘리포니아 인스티튜트 오브 테크놀로지 | 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법 |
AU2015339290B8 (en) | 2014-10-30 | 2021-08-26 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
CN109642904A (zh) | 2016-05-23 | 2019-04-16 | 加州理工学院 | 调节肠微生物群来治疗神经退行性病症 |
EP3565636B1 (en) * | 2017-01-09 | 2024-01-03 | California Institute of Technology | Use of gut microbiota in the diagnosis of parkinson's disease |
US11147792B2 (en) | 2017-05-15 | 2021-10-19 | Axial Therapeutics, Inc. | Inhibitors of microbially induced amyloid |
EP3697799A1 (en) * | 2017-10-19 | 2020-08-26 | Elysium Health, Inc. | Prevention and treatment of tdp-43 associated diseases |
CN113072490B (zh) * | 2021-03-26 | 2022-08-16 | 中国海洋大学 | 一种替吡法尼喹啉酮中间体的高效合成方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU169186B (pt) * | 1974-06-13 | 1976-10-28 | ||
AU711142B2 (en) * | 1995-12-08 | 1999-10-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives |
CN1326847C (zh) * | 1995-12-22 | 2007-07-18 | 先灵公司 | 三环酰胺类用于抑制g-蛋白功能及治疗增生疾病 |
US5939439A (en) * | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO2000034437A2 (en) * | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US20010051642A1 (en) * | 2000-04-17 | 2001-12-13 | Kyunghye Ahn | Method for treating Alzheimer's disease |
JP4312012B2 (ja) | 2003-09-12 | 2009-08-12 | トヨタ自動車株式会社 | パラコート(登録商標)耐性遺伝子並びに維管束及びトライコーム特異的プロモーター |
CA2559282A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
CA2559221A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
DK2362218T3 (en) * | 2004-11-05 | 2014-11-17 | Janssen Pharmaceutica Nv | Methods for monitoring the effectiveness of farnesyl transferase |
WO2007042465A2 (en) * | 2005-10-07 | 2007-04-19 | Novartis Ag | Combinati0n of nilotinib with farnesyl transferase inhibitors |
WO2007075923A2 (en) * | 2005-12-23 | 2007-07-05 | Link Medicine Corporation | Treatment of synucleinopathies |
US20100184803A1 (en) * | 2007-03-09 | 2010-07-22 | Link Medicine Corporation | Treatment of Lysosomal Storage Diseases |
WO2008137692A1 (en) * | 2007-05-03 | 2008-11-13 | Link Medicine Corporation | Treatment of synucleinopathies |
WO2009036275A1 (en) * | 2007-09-13 | 2009-03-19 | Link Medicine Corporation | Treatment of neurodegenerative diseases using indatraline analogs |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
PT2276485E (pt) * | 2008-04-24 | 2014-10-20 | Bristol Myers Squibb Co | Utilização de epotilona d no tratamento de doenças tauassociadas que compreendem a doença de alzheimer |
-
2009
- 2009-11-13 JP JP2011536511A patent/JP2012508765A/ja not_active Withdrawn
- 2009-11-13 US US13/129,360 patent/US20110294794A1/en not_active Abandoned
- 2009-11-13 EP EP09759841A patent/EP2358370A2/en not_active Withdrawn
- 2009-11-13 CA CA2743709A patent/CA2743709A1/en not_active Abandoned
- 2009-11-13 WO PCT/US2009/064442 patent/WO2010057028A2/en active Application Filing
- 2009-11-13 AU AU2009313906A patent/AU2009313906A1/en not_active Abandoned
- 2009-11-13 BR BRPI0921113A patent/BRPI0921113A2/pt not_active IP Right Cessation
- 2009-11-13 WO PCT/US2009/064375 patent/WO2010056985A2/en active Application Filing
- 2009-11-13 MX MX2011005095A patent/MX2011005095A/es not_active Application Discontinuation
- 2009-11-13 US US12/618,265 patent/US20100160372A1/en not_active Abandoned
-
2011
- 2011-05-12 IL IL212835A patent/IL212835A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010057028A2 (en) | 2010-05-20 |
WO2010057028A3 (en) | 2010-12-02 |
WO2010056985A8 (en) | 2011-01-06 |
US20110294794A1 (en) | 2011-12-01 |
US20100160372A1 (en) | 2010-06-24 |
CA2743709A1 (en) | 2010-05-20 |
EP2358370A2 (en) | 2011-08-24 |
IL212835A0 (en) | 2011-07-31 |
WO2010056985A2 (en) | 2010-05-20 |
WO2010057028A9 (en) | 2010-09-02 |
JP2012508765A (ja) | 2012-04-12 |
WO2010056985A3 (en) | 2010-10-21 |
AU2009313906A1 (en) | 2010-05-20 |
WO2010056985A9 (en) | 2010-08-19 |
MX2011005095A (es) | 2011-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2020023I1 (el) | Αναστολεiς βητα-λακταμασων | |
BRPI0921113A2 (pt) | tratamento de proteinopatias usando um inibidor de farnesil transferase. | |
LTPA2017039I1 (lt) | Pirolopirimidino junginiai, kaip CDK inhibitoriai | |
CY2017016I1 (el) | Αναστολεις πρωτεασωματος | |
BRPI0911175A2 (pt) | conjuntos de válvula | |
DK2500047T3 (da) | Lægemiddelfrigivende coatinger til medicinske indretninger | |
BRPI0817843A2 (pt) | Inibidores da quinase c-fms | |
BRPI0922880A2 (pt) | compostos inibidores de quinase | |
BRPI0918564A2 (pt) | inibidores | |
BRPI0814797A2 (pt) | Inibidores dna-pk | |
BR112012001070A2 (pt) | inibidores de ativação de complementos | |
BRPI0908513A2 (pt) | válvula | |
DK2254637T3 (da) | Kateter | |
BRPI0909422A2 (pt) | conjunto de artigos. | |
BRPI0912152A2 (pt) | umbilical | |
BRPI0921856A2 (pt) | valvula de alívio | |
BRPI0908866A2 (pt) | mastiques | |
BRPI1012963A2 (pt) | compostos inibidores da 11-beta-hidroxisteróide dehidrogenase tipo 1. | |
BRPI0919100A2 (pt) | Inibição de corrosão. | |
BRPI0905872A2 (pt) | Válvula de pressão mínima | |
ATE522533T1 (de) | Pyrazolopyrimidinonkinaseinhibitor | |
IT1394067B1 (it) | Valvola | |
BR112012003044A2 (pt) | inibidores de catepsina c. | |
DE112009002496A5 (de) | Druckbehälter | |
NO20082548L (no) | Teine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2371 DE 14-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |